Organisation paid for research Program year 2024 Source: CMS Open Payments

Omega Research Maitland

Neither a doctor nor a teaching hospital

Research payments

$2,377,817

739 payments

Through program year 2024, Omega Research Maitland is reported as receiving $2,377,817 in research payments, across 739 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $13,026 14
2023 Research $120,988 23
2022 Research $435,209 83
2021 Research $547,108 95
2020 Research $356,776 176
2019 Research $904,711 348

Breakdown

Who paid Research payments · program years 2019–2024
  1. AbbVie, Inc. $1,048,988 447 payments
  2. Sunovion Pharmaceuticals Inc. $763,303 56 payments
  3. Pfizer Inc. $185,787 83 payments
  4. Sumitomo Pharma America, Inc. $93,613 4 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $83,441 76 payments
  6. Shire North American Group Inc $80,899 38 payments
  7. Celgene Corporation $43,297 4 payments
  8. Intercept Pharmaceuticals, Inc. $42,542 14 payments
  9. Sanofi US Services Inc. $9,700 10 payments
  10. Sanofi Pasteur Inc. $9,400 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. M16-283 $382,137 203 payments
  2. M16-006 $239,194 48 payments
  3. A Phase 1, Open-label, Fixed Sequence Crossover Study to Investigate the Effect of Coadministration of Paroxetine on the Pharmacokinetics of SEP-363856 in Extensive CYP2D6 Metabolizers in Renal Insufficiency $213,898 14 payments
  4. A Phase 1, Open-label, Fixed Sequence Crossover Study to Investigate the Effect of Coadministration of Paroxetine on the Pharmacokinetics of SEP-363856 in Extensive CYP2D6 Metabolizers in Renal Insufficiency $213,402 18 payments
  5. A Phase 1, Open-label, Fixed Sequence Crossover Study to Investigate the Effect of Coadministration of Paroxetine on the Pharmacokinetics of SEP-363856 in Extensive CYP2D6 Metabolizers in Hepatic Insufficiency $186,025 13 payments
  6. A Phase 1 Randomized Multicenter Doubleblind Sponsor Open Placebocontrolled Single and Multiple Doseescalation Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Pf06835375 in Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis $184,454 76 payments
  7. A Phase 1, Open-label, Fixed Sequence Crossover Study to Investigate the Effect of Coadministration of Paroxetine on the Pharmacokinetics of SEP-363856 in Extensive CYP2D6 Metabolizers in Hepatic Insufficiency $149,979 11 payments
  8. A Phase 1 Open-label Pharmacokinetic Study of SEP?363856 in Subjects with Mild Moderate or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Function $93,613 4 payments
  9. M14-234 $65,018 22 payments
  10. M14-431 $60,070 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record